Abstract 1431P
Background
Neoadjuvant chemotherapy combined with immunotherapy (nCIT) is emerging as a promising strategy for treating patients with esophageal cancer. We aimed to develop a novel, voxel-level radiomics deep learning model to predict the pathological complete response (pCR) to nCIT in esophageal squamous cell carcinoma (ESCC).
Methods
We included 745 ESCC patients from three institutions, comprising a training set (N=500, institution 1), test-set-1 (N=86, institution 1), test-set-2 (N=34, institution 2), and test-set-3 (N=125, institution 3). All patients underwent nCIT and received a pathological evaluation post-surgery. A total of 104 distinct radiomic features were extracted from the tumor areas in CT images prior to nCIT. Features demonstrating predictive power with an area under the receiver operating characteristic curve (AUROC) exceeding 0.6 were retained. Each selected radiomics feature map, along with the original image, was input into a vision transformer model as a separate channel. The Shapley Additive exPlanations method was employed to visualize feature importance and identify predictive regions within the tumor, enhancing the model’s interpretability. For baseline comparison, we also constructed a clinical model using only clinical factors, and compared it against traditional radiomics and ResNet models.
Results
The voxel-level radiomics deep learning model achieved an AUC of 0.825 with an accuracy of 76.2% in test-set-1, 0.751 and 68.5% in test-set-2, and 0.819 with 78.1% in test-set-3, respectively. It demonstrated superior predictive performance compared to the clinical model, traditional radiomics model, and ResNet model.
Conclusions
This innovative and noninvasive voxel-level radiomics deep learning approach offers an efficient and accurate approach of predicting treatment response to nCIT in ESCC, potentially benefiting clinical decision-making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Z. Zhang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1416P - First-line tislelizumab combined with bevacizumab and CAPOX for metastatic gastroesophageal adenocarcinoma (mGEA) with PD-L1 CPS<5: Updated results of a phase II, prospective, single-arm study
Presenter: guanghai dai
Session: Poster session 17
1417P - Comparative efficacy and safety of tislelizumab versus anti-PD-1 treatments in second-line esophageal squamous cell carcinoma: Simulated treatment comparisons
Presenter: Elizabeth Smyth
Session: Poster session 17
1418P - Tumor microenvironment B-cell abundance and survival in resectable gastric cancer: A translational analysis from the CLASSIC trial
Presenter: Manavi Sachdeva
Session: Poster session 17
1419P - Osemitamab (TST001) plus nivolumab and CAPOX as the first-line therapy for the patients with advanced G/GEJ cancer (TranStar102)
Presenter: Lin Shen
Session: Poster session 17
1420P - Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC)
Presenter: Seiya Sato
Session: Poster session 17
1421P - Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer - (HERIZON)
Presenter: Joshua Tobias
Session: Poster session 17
1422P - First-line rilvegostomig (rilve) + chemotherapy (CTx) in patients (pts) with HER2-negative (HER2–) locally advanced unresectable or metastatic gastric cancers: First report of GEMINI-Gastric sub study 2
Presenter: Fernando Rivera Herrero
Session: Poster session 17
1423P - Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial
Presenter: Elena Elimova
Session: Poster session 17
1424P - Maintenance capecitabine plus ramucirumab after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma (OGA): Final analysis from the PLATFORM trial
Presenter: Anderley Gordon
Session: Poster session 17